Retracted: Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells

@article{Kikuno2008RetractedGM,
  title={Retracted: Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells},
  author={Nobuyuki Kikuno and Hiroaki Shiina and Shinji Urakami and Ken Kawamoto and Hiroshi Hirata and Yuichiro Tanaka and Shahana Majid and Mikio Igawa and Rajvir Dahiya},
  journal={International Journal of Cancer},
  year={2008},
  volume={123}
}
The above article, published online on 22 April 2008 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the authors, the journal Editor in Chief, Prof. Peter Lichter, and John Wiley & Sons Ltd. The retraction has been agreed due to errors identified in Figs, 3, 4, and 5. The concerns about these figures cannot be resolved because the original data can no longer be retrieved. 
Targeting DNA Methyltranferases in Urological Tumors
TLDR
This review highlights the critical role of DNA methylation in urological cancers and summarizes the available data on pre-clinical assays and clinical trials with DNMT inhibitors in bladder, kidney, prostate, and testicular germ cell cancers.
Genistein, an epigenome modifier during cancer prevention
TLDR
Both in vitro and in vivo studies in the field that investigate the effect of genistein on histone modifications and DNA methylation are discussed, and the promising role ofgenistein in cancer prevention and therapeutic applications is discussed.
Epigenomics, Pharmacoepigenomics, and Personalized Medicine in Cervical Cancer
TLDR
A detailed description of recent developments in the field of epigenetics and its impact on personalized medicine to manage cervical cancer is provided.
Epigenetic Basis of Polyphenols in Cancer Prevention and Therapy
TLDR
The dynamic landscapes of epigenetic patterns implicate in genetic expression, post-translational modifications as well as transcribing multivariate signals into the specific program to alter the functions of tumor suppressing genes and oncogenes.
The role of the deubiquitinating enzyme CYLD and its substrate BCL-3 in solid tumors
TLDR
CYLD down-regulation is a risk factor for development and progression of HCC mediated through activation of JNK1 (Less) and results suggest that SRF is a positive regulator of CYLD expression, which in turn reduces the mitogenic activation of wild type MEF cells.
DNA Methyltransferases Inhibitors from Natural Sources.
TLDR
Several polyphenols, flavonoids, antraquinones, and others are described able to inhibit DNMTs activity and/or expression, thus decreasing the methylation/silencing of different genes involved in tumorigenesis.
Ubiquitin chain cleavage: CYLD at work.
DNA Methylation and Flavonoids in Genitourinary Cancers
TLDR
Several commonly methylated genes and flavonoids used to modulate DNA methylation in the prevention of genitourinary cancers are discussed.
FOXO 3 a : A Potential Target in Prostate Cancer
TLDR
Survival of established cancer cells after chemotherapeutic exposure requires FOXO mediated ROS responses, and development of oxidative resistance is associated with increased expression of FOXO3a, NAMPT, and SIR1 proteins.
...
...

References

SHOWING 1-10 OF 61 REFERENCES
hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
Oncogenic PI3K deregulates transcription and translation
TLDR
The recent discoveries of cancer-specific mutations in PIK3CA, the gene that encodes the catalytic subunit p110 α of PI3K, have heightened the interest in the oncogenic potential of this lipid kinase and have made p110α an ideal drug target.
Genistein alters methylation patterns in mice.
In this study we examine the effect of the phytoestrogen genistein on DNA methylation. DNA methylation is thought to inhibit transcription of genes by regulating alterations in chromatin structure.
Inhibition of SIRT1 Reactivates Silenced Cancer Genes without Loss of Promoter DNA Hypermethylation
TLDR
It is shown that SIRT1 localizes to promoters of several aberrantly silenced tumor suppressor genes (TSGs) in which 5′ CpG islands are densely hypermethylated, but not to these same promoters in cell lines in which the promoters are not hyper methylated and the genes are expressed.
SIRT1: tumor promoter or tumor suppressor?
Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB
TLDR
It is reported here that inhibition of one of these enzymes, the familial cylindromatosis tumour suppressor gene (CYLD), having no known function, enhances activation of the transcription factor NF-κB, and this effect can be relieved by aspirin derivatives that inhibit NF-σB activity.
Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer
TLDR
New putative NSCLC growth regulatory genes and epigenetic disease biomarkers that may enhance early detection strategies and serve as therapeutic targets are revealed.
Inhibition of Nuclear Factor κB Activation in PC3 Cells by Genistein Is Mediated via Akt Signaling Pathway
TLDR
The inhibition of Akt and NF-kappaB activity and their cross-talk provide a novel mechanism by which genistein inhibits cell growth and induces apoptotic processes in tumorigenic but not in nontumorigenic prostate epithelial cells.
Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway.
  • Yiwei LiF. Sarkar
  • Biology
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2002
TLDR
The inhibition of Akt and NF-kappaB activity and their cross-talk provide a novel mechanism by which genistein inhibits cell growth and induces apoptotic processes in tumorigenic but not in nontumorigenic prostate epithelial cells.
...
...